VRTX Stock Recent News

VANCOUVER, British Columbia, June 23, 2025 (GLOBE NEWSWIRE) -- Vortex Energy Corp. (CSE: VRTX) (OTC: VTECF) (FSE: AA3) (“Vortex” or the “Company”) announces that it has appointed Independent Trading Group, Inc. (Address: 420, 33 Yonge Street, Toronto, ON, Canada, M5E 1G4; Website: www.itg84.com; Contact: Chris Kaplan; Email: chriskaplan@itg84.com) (“ITG”) as a market maker for its common shares traded on the Canadian Securities Exchange (the “CSE”).

BOSTON & OSAKA, Japan--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Ono Pharmaceutical Co., Ltd. (OTCMKTS: OPHLY) today announced an exclusive collaboration and license agreement for the development and commercialization of Vertex's povetacicept in Japan and South Korea. Povetacicept is a recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines with best-in-class potential b.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX ) American Diabetes Association (ADA) 85th Scientific Sessions Conference June 20, 2025 8:15 PM ET Company Participants James Markmann - Corporate Participant Michael Rickels - Corporate Participant Felicia Pagliuca - Corporate Participant Susie Lisa - Senior Vice President of Investor Relations Conference Call Participants Adam Ferrari - JPMorgan Chase & Co, Research Division Bryan Russell Dollinger - Leerink Partners LLC, Research Division Dina Elmonshed - Jefferies LLC, Research Division Jarwei Fang - Unidentified Company Liisa Ann Bayko - Evercore ISI Institutional Equities, Research Division Malcolm Hoffman - BMO Capital Markets Equity Research Mohit Bansal - Wells Fargo Securities, LLC, Research Division Terence C. Flynn - Morgan Stanley, Research Division a division of S&P - Unidentified Company Susie Lisa Thanks for your patience.

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced simultaneous presentation and publication of updated data from the Phase 1/2 portion of the Phase 1/2/3 FORWARD-101 clinical trial of zimislecel (VX-880), an investigational stem cell-derived, fully differentiated islet cell therapy, in people with type 1 diabetes (T1D) with impaired hypoglycemic awareness and severe hypoglycemic events (SHEs). The data were featured in an oral presentation at the Americ.

In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $440.87, denoting a -1.68% move from the preceding trading day.

Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Popular themes on Wall Street today include artificial intelligence (AI), the market for weight management medicines, and the potential impact of tariffs on broader equities and the economy. In 10 years, there will probably be a different set of trending topics on The Street, but those changes won't stop the market from delivering competitive returns over the next decade.

You're unlikely to have a warm-and-fuzzy feeling after buying some stocks. Instead, some stocks can keep you awake at night because of their high volatility and risk.

Buy-and-hold investing is a time-tested strategy that rewards patience and discipline.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX ) Goldman Sachs 46th Annual Global Healthcare Conference Call June 10, 2025 2:40 PM ET Company Participants David M. Altshuler - Executive VP & Chief Scientific Officer Reshma Kewalramani - CEO, President & Director Conference Call Participants Salveen Jaswal Richter - Goldman Sachs Group, Inc., Research Division Salveen Jaswal Richter Good afternoon, everyone.